Skip to main content

Table 3 Baseline characteristics of HCC patients with regular surveillance

From: Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation

Characteristics

Low risk group

High risk group

Short interval

Long interval

P

Short interval

Long interval

P

Patients

199 (75.7)

64 (24.3)

 

145 (79.7)

37 (20.3)

 

Pre-TACE

22 (11.1)

11 (17.2)

0.284

71 (49.0)

12 (32.4)

0.106

Age (yrs.)

55.0 (17.5)

54.0 (19.5)

0.962

56.0 (14)

61.0 (21)

0.058

Male

177 (88.9)

61 (95.3)

0.206

135 (93.1)

35 (94.6)

1.000

Tumor number

  

1.000

  

0.971

 Singular

199 (100.0)

64 (100.0)

 

69 (47.6)

18 (48.6)

 

 Multiple

–

–

 

76 (52.4)

19 (51.4)

 

Tumor size

     

0.631

 ≤ 3 cm

199 (100.0)

64 (100.0)

 

34 (37.2)

16 (43.2)

 

 > 3 cm

–

–

 

91 (62.8)

21 (56.8)

 

Risk area

50 (25.1)

14 (21.9)

0.719

39 (26.9)

9 (24.3)

0.914

AFP ≥200 ng/ml

67 (33.7)

10 (15.6)

0.009

86 (59.3)

20 (54.1)

0.695

Hb (109/L)

143.0 (2.80)

145.5 (19.2)

0.331

142.0 (21.2)

142.0 (22.1)

0.367

PLT (109/L)

131.0 (96.0)

129.5 (95.9)

0.896

105.1 (85.0)

132.0 (98.0)

0.452

RBC (109/L)

4.5 (0.8)

4.8 (0.8)

0.013

4.6 (0.8)

4.5 (0.9)

0.556

WBC (109/L)

5.3 (2.5)

5.4 (2.5)

0.579

5.2 (2.5)

5.80 (0.9)

0.357

ALB (g/L)

41.9 (7.9)

42.5 (5.6)

0.671

41.2 (5.8)

40.3 (6.7)

0.804

ALT (U/L)

34.1 (23.4)

37.2 (29.5)

0.229

37.1 (29.1)

36.0 (25.3)

0.773

AST (U/L)

32.3 (20.0)

33.5 (20.0)

0.802

35.7 (22.3)

35.5 (28.6)

0.868

TBIL (μmol/L)

14.4 (9.0)

15.2 (6.8)

0.678

16.0 (11.8)

14.3 (5.2)

0.137

Child-Pugh grade

  

0.732

  

0.348

 A

191 (96.0)

44 (95.3)

 

138 (95.2)

44 (100.0)

 

 B

8 (4.0)

3 (4.7)

 

7 (4.80)

0 (0.00)

 

PT (seconds)

12.3 (1.7)

12.1 (1.6)

0.135

12.3 (1.8)

12.4 (1.8)

0.837

Viral hepatitis

184 (92.5)

59 (92.2)

1.000

137 (94.5)

34 (91.9)

0.838

Cirrhosis

159 (79.9)

51 (79.7)

1.000

125 (86.2)

26 (70.3)

0.040

  1. Abbreviations: TACE Transcatheter arterial chemoembolization, AFP alpha-fetoprotein, Hb Hemoglobin, PLT platelet, RBC red blood cell, WBC white blood cell, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, PT prothrombin time
  2. Values are presented as the median (IQR) or n (%)